Navigation Links
U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
Date:8/12/2008

amended. Forward-looking statements, including the Company's expectations related to the U.S. NCI Phase 2 systemic administration clinical trial for patients with metastatic melanoma, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
3. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
4. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
5. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
6. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  CytomX Therapeutics, Inc., a biopharmaceutical company developing ... the filing of a registration statement on Form S-1 ... to a proposed initial public offering of its common ... the price range for the offering have not yet ... under the symbol "CTMX" on the NASDAQ Global Market. ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Originally discovered ... as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory ... by Senju Pharmaceutical Co., Ltd under the trade ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... N.C., June 20, 2011 Pharmaceutical Institute, the ... pharmaceutical and biotech industry and a subsidiary of ... updates to its Therapeutic Area Essentials™ ... disease state training for pharmaceutical and biotech R&D ...
... dreamed of becoming a pilot for as long as he can ... child opting to play with toy planes instead of cars, and ... a family trip to Disney World.  At 8-years old Baniecki scribbled ... airline pilot and placed it into a time capsule.  Ten years ...
Cached Medicine Technology:Therapeutic Area Essentials "Class of 2011" Brings Current Disease State Training to Pharma 2Pilot's Dream Comes True Thanks to New Robotic Surgery 2Pilot's Dream Comes True Thanks to New Robotic Surgery 3Pilot's Dream Comes True Thanks to New Robotic Surgery 4
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle ... 15 seconds of unique footage that users can shrink and stretch in the Final ... more. Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... the company to freely market and sell Arterosil and Arterosil HP, and that ... Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... No Malaria Day at the Zoo to celebrate children helping children, a thank ... their congregations throughout West Ohio have contributed to the United Methodist initiative to ...
(Date:8/28/2015)... ... , ... For Dallas, the time is nearing for the annual Heart Walk, ... , The American Heart Association hosts their well-known Heart Walk to raise money in ... difference can be made. Walkers can participate in the cause and someone can also ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... with profound hearing disabilities and President A.P.J.Abdul Kalam today ... to intensify their drive to reduce the number of ... the 3rd Cochlear Implant Group of India Conference in ... with severe hearing disability, 0.9 million people with moderate ...
... has been found to have less side effects and ... the allergen is given as a vaccine in order ... antibodies which are already present helps to counteract the ... injections against allergy diseases such as hay fever, cat ...
... leader Colgate-Palmolive Company has entered into an alliance with ... designed to fight against pre-cancerous //conditions in the oral ... this end Colgate purchased $20 million of Introgen shares ... by Introgen. Introgen has a wide range of molecular ...
... November issue of the Journal of the National Cancer Institute, ... treatment, and patients treated with the higher chemotherapy dose had ... testicular cancer is the most common cancer among 20-40 year ... age at which they are starting a family, and the ...
... that rheumatoid arthritis patients respond differently to the same ... new study now explains that it is due to ... following experiments conducted on animal models of mouse that ... such complex behaviors could enable physicians make an individualized ...
... FDA approved long-term treatment regime for patients with treatment ... now being offered to patients at NewYork-Presbyterian Hospital/Columbia University ... first treatment specifically approved for TRD in patients over ... been unsuccessful atleast in four or more of the ...
Cached Medicine News:Health News:Kalam Appeals to Eradicate Hearing Disability 2Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Decline in Paternity Rates Following Treatment for Testicular Cancer 2Health News:Study Offers Insights Into Treatment Of Rheumatoid Arthritis 2Health News:FDA Approved Nerve-Stimulation Therapy Now Available In New York 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: